Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026)OBTAINS CLINICAL TRIAL APPROVAL

BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026)OBTAINS CLINICAL TRIAL APPROVAL

November 12, 2024

1112_00.png

1112_01.png

Next: VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat